Archive for July, 2009
FDA Grants Delcath Systems, Inc. (DCTH) Orphan-Drug Designation for Doxorubicin
(PRNewswire-FirstCall) — Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath’s request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.
Doxorubicin is a common chemotherapy agent shown to be effective for the treatment of HCC, as well as hematological malignancies, soft tissue sarcomas, and many types of carcinoma. Delcath Systems performed early clinical studies of doxorubicin with its Percutaneous Hepatic Perfusion (PHP(TM)) technology, which allows physicians to deliver significantly higher doses of anti-cancer drugs to the liver without exposing the patient’s entire body to those same potent levels of drug, with very encouraging results. The company plans to perform the clinical work necessary for a submission to the FDA of PHP(TM) with doxorubicin for treatment of HCC.
“Following our orphan-drug designations for several applications of melphalan, this new designation for doxorubicin is an important step towards securing our leadership position in the regional treatment of liver cancers,” said Eamonn Hobbs, President and CEO of Delcath Systems. “Patients with HCC have few good options. Doxorubicin has an established track record as a treatment for several cancers, including HCC. We believe that Delcath’s Percutaneous Hepatic Perfusion(TM) System can deliver high-dose doxorubicin to the liver and spare the patient from systemic exposure, thereby creating a new, tolerable and effective treatment option for these patients. It is our plan to aggressively pursue this indication with the required clinical work.”
Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of marketing exclusivity after gaining FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath’s novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient’s bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company’s intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company’s website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
SOURCE Delcath Systems, Inc.
Ness Technologies, Inc. (NSTC)
Ness Technologies, Inc. provides Information Technology (IT) business services and solutions to more than 500 clients in the commercial, industrial and government sectors. The company is known for its specialized expertise in software product engineering; system integration, application development and consulting; and software distribution. The company delivers its services and solutions through offices located in 18 different countries with a work force of approximately 8,000 experienced professionals.
Ness Technologies has formed strategic partnerships with many leading global software and infrastructure vendors to capitalize on a wide array of technologies and innovation. The company continuously evaluates and pursues other potential partners to deliver the most effective and advanced solutions to its clients. By achieving the highest level of certification with many of its partners, Ness Technologies has been able to leverage its early access to new product offerings to influence the development of new products and offerings.
Despite economic turbulence, the company’s balance sheet remains strong. As of last report, the company held $35.0 million in cash and cash equivalents, and $627.5 million in other assets. Total current and long-term liabilities were reported at $332.4 million. Stockholders’ equity totals approximately $330.2 million providing a book value per share of $8.69, which is significantly higher than the current market price.
For the second quarter of 2010, Ness Technologies reported revenues of $139.7 million, an increase of 10% from last year. The company said it continues to expect top line revenue growth and margin expansion throughout the rest of the year, with third quarter results in line with second quarter results, and fourth quarter results significantly better than third quarter results.
Currently, 2.16% of the shares outstanding are held by insiders and 68.50% are held by institutions. Two analysts believe the company is a “Strong Buy, two believe it’s a “Buy”, and one believes it’s a “Hold”. Next year analysts expect earnings per share of $0.57 compared to this year’s $0.43. Next year’s revenues are anticipated to total $604.4 million versus this year’s $565.5 million.
Key statistics (8/26/10):
Market cap: $161.5 Million
P/S Ratio: 0.32 versus industry average of 1.93
5-Year Avg. Sales Growth of 12.44% versus industry average of 14.81%
5-Year Avg. Gross Margin of 27.6% versus industry average of 26.8%
Debt/Equity Ratio: 0.24 versus industry average of 0.25
Current Ratio: 1.3 versus industry average of 2.7
Quick Ratio: 1.3 versus industry average of 2.7
Book Value/Share: $8.69 versus current market price of $4.25
Recent News
Featured Profile On Homepage
Bull of the Week
Astrotech Corp.
(NASDAQ: ASTC)
Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection. The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name. In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.
TraderPower Featured Companies
- Astrotech Corp. (NASDAQ: ASTC)
- Cepton Inc. (NASDAQ: CPTN)
- Clene Inc. (NASDAQ: CLNN)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)
- Freight Technologies Inc. (NASDAQ: FRGT)
- InMed Pharmaceuticals Inc. (NASDAQ: INM)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- Mullen Automotive Inc. (NASDAQ: MULN)
- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)
Top Small Cap Market News
- $ASTC New AI Model Can Detect Diseases by Analyzing Visual Maps
- $DLMI InvestorNewsBreaks – Diamond Lake Minerals Inc.’s (DLMI) Leadership in Tokenization of Real Estate Assets Spotlighted in Recent Article
- $TURB GreenEnergyBreaks – Turbo Energy S.A. (NASDAQ: TURB) Providing ‘Best on the Market’ AI-Driven System
- $TURB Turbo Energy (NASDAQ: TURB) Aligned with Rising EU and U.S. Renewable Energy Targets
- $FSTTF Shanghai Unveils Plan Aimed at Improving ESG
- $GEMZ TinyGemsBreaks – GEMXX Corp. (GEMZ) Poised for Opportunity in Burgeoning Indian Market
- InvestorNewsBreaks – Upstream Empowering Issuers with Access to Global Investor Base, Suite of Innovative Tools
- InvestorNewsBreaks – Astiva Health Addressing Challenges of Traditional Caregiving Structures
- $SIGY BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space
- $SFWJ Reports Suggest DEA Resisting Pressure from White House to Reclassify Marijuana
- $MULN NYT Report Shows Disinterest in EVs Still Rife in US
- $SNES InvestorNewsBreaks – SenesTech Inc. (NASDAQ: SNES) Is Expanding Global Reach with Innovative Products
- $FNICF Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Advances Exploration Program, Closes Private Placement
- $FNICF MiningNewsBreaks – Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Well Positioned to Capitalize on World’s Ongoing Energy Transition
Recent Posts
- $FNICF MiningNewsBreaks – Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Well Positioned to Capitalize on World’s Ongoing Energy Transition
- $FNICF Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Advances Exploration Program, Closes Private Placement
- $SNES InvestorNewsBreaks – SenesTech Inc. (NASDAQ: SNES) Is Expanding Global Reach with Innovative Products
- $MULN NYT Report Shows Disinterest in EVs Still Rife in US
- $SFWJ Reports Suggest DEA Resisting Pressure from White House to Reclassify Marijuana
- $SIGY BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space
- InvestorNewsBreaks – Astiva Health Addressing Challenges of Traditional Caregiving Structures
- InvestorNewsBreaks – Upstream Empowering Issuers with Access to Global Investor Base, Suite of Innovative Tools
Recent Comments
Archives
- March 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009